The studies were paused for less than a week.
The post AstraZeneca resumes UK clinical trials of its coronavirus vaccine after a safety pause appeared first on Motley Fool Australia. –
This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.
This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.
Less than a week after investors learned that AstraZeneca (NYSE: AZN) had paused the clinical trials testing its coronavirus vaccine, AZD1222, the UK’s Medicines Health Regulatory Authority (MHRA) determined it was safe for the company to restart the studies.
The pause was triggered by an adverse event – clinical-trial speak for a potential side effect – in one participant in the clinical trial. Pauses, which are fairly common in large clinical trials, give companies time to determine if the adverse event was caused by the vaccine. An independent committee for the UK studies reviewed the data and recommended to the MHRA that the clinical trials were safe to resume.
About 18,000 people have been vaccinated with AZD1222, which is also being tested in phase 3 clinical trials in Brazil, South Africa, and the US AstraZeneca didn’t say when the clinical trials outside of the UK would be restarted.
AstraZeneca also didn’t disclose publicly what the illness was, but multiple sources have reported that the company’s CEO Pascal Soriot said on a call organised by the investment bank J.P. Morgan that the patient experienced serious neurological symptoms that were consistent with transverse myelitis, a spinal inflammatory disorder.
Shares of AstraZeneca were up just 0.7% in late-afternoon trading on the news, but the drugmaker had already regained most of the decline its shares suffered after the clinical-trial pause was disclosed.
This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.
These 3 stocks could be the next big movers in 2020
When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for more than eight years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*
In this FREE STOCK REPORT, Scott just revealed what he believes are the 3 ASX stocks for the post COVID world that investors should buy right now while they still can. These stocks are trading at dirt-cheap prices and Scott thinks these could really go gangbusters as we move into ‘the new normal’.
Find out the names of our 3 Post COVID Stocks – For FREE!
*Returns as of 6/8/2020
More reading
- Pfizer says it could know if its COVID-19 vaccine candidate works in October
- The surefire vaccine winner following AstraZeneca’s COVID-19 trial pause
- What if more than one company wins the coronavirus vaccine race?
- Coronavirus vaccine race: 7 key things you’ll want to know
- AstraZeneca coronavirus vaccine clinical trial paused
Brian Orelli, PhD and The Motley Fool have no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.
The post AstraZeneca resumes UK clinical trials of its coronavirus vaccine after a safety pause appeared first on Motley Fool Australia.
This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.
